Left ventricular twist mechanics and its relation with aortic stiffness in chronic kidney disease patients without overt cardiovascular disease

Samir Sulemane1*, Vasileios F. Panoulas2, Klio Konstantinou2, Athanasios Bratsas2, Frederick W. Tam3, Edwina A. Brown3 and Petros Nihoyannopoulos1

Abstract

Background: Recent studies hypothesized left ventricular (LV) twist as a potential biomarker for evaluation of subclinical myocardial disease, however its relationship with aortic stiffness has yet to be investigated. Chronic kidney disease (CKD) has been identified as a risk factor for both myocardial and arterial disease. As such we sought to explore the relationship between aortic stiffness and LV twist in CKD patients without known cardiovascular disease (CVD).

Methods: In this prospective, observational study we enrolled 106 CKD patients (Stages 1 to 5) with normal LVEF as assessed by conventional echocardiography. Aortic stiffness was measured using aortic pulse wave velocity (aPWV). We defined increased aPWV as $\geq 10$ m/s. LV Twist was measured using two-dimensional speckle tracking echocardiography.

Results: Patients with increased aPWV had higher LV twist ($p = 0.002$) but similar LVEF ($p = 0.486$). Aortic PWV correlated crudely with age ($p < 0.001$), the presence of diabetes ($p < 0.001$), hypertension ($p < 0.001$), eGFR ($p < 0.001$), LVMI ($p = 0.01$), e/e' ($p < 0.001$) and LV twist ($p = 0.003$). In multivariable analyses after adjusting for age, gender, cardiovascular risk factors and hypertensive medication, aPWV was independently associated with LV twist ($\beta = 0.163, p = 0.025$).

Conclusions: Aortic stiffness independently associates with LV Twist in asymptomatic CKD patients. These findings suggest a close interaction between LV twist mechanics and arterial remodeling even before CVD becomes clinically relevant.

Keywords: Chronic kidney disease, LV twist, Speckle tracking echocardiography, Arterial stiffness, Aortic pulse wave velocity

Background

Recent data suggests that chronic kidney disease (CKD) patients develop both arterial and myocardial dysfunction at an early stage of the disease. Wang and colleagues identified that increased arterial stiffness is evident as early as CKD stage 2 [1]. Even though obstructive epicardial atherosclerotic disease is not an uncommon finding in patients with advanced CKD, early atherosclerotic changes in the macro- and microvasculature result in arterial stiffness that subsequently leads to structural myocardial disease [2, 3]. These pathophysiological features are manifested by a high risk of lethal arrhythmias, congestive heart failure and stroke [3]. Extensive research on methods for assessing arterial stiffness has led to a consensus that aortic pulse wave velocity (aPWV) should be regarded as the ‘gold standard’ [4]. Aortic PWV has been validated in a variety of clinical settings including in CKD [5–7].

Panoulas et al identified Left Ventricular (LV) twist as a potential marker of sub clinical LV systolic dysfunction in CKD patients with normal ejection fraction, as measured by conventional 2D echocardiography [8]. Abnormal LV twist values were seen as early as CKD stage 3. LV twist refers to the systolic twisting motion resulting from basal clockwise rotation and apical counter-clockwise rotation (when viewed from the apex) [9]. Previous data attribute up to 40 % of LV stroke volume to ventricular twist dynamics [10]. Furthermore LV twist has proven to be a
the four-variable equation in the Modification of Diet in Renal Disease study [13].

Echocardiographic assessment
Transthoracic echocardiography was performed using a commercially available system (Vivid 7, GE Vingmed Ultrasound, Horten, Norway) by a single, accredited echocardiographer according to a standardised protocol. All echocardiographic parameters were measured offline in batches by one observer blinded to clinical and outcome data. Interventricular septum thickness, posterior wall thickness, LV mass index (LVMI), tissue Doppler imaging S’ wave (TDI S’), left atrial (LA) dimension and LVEF were measured according to the recommendations of the American Society of Echocardiography [14].

2-dimensional speckle tracking echocardiography
Speckle tracking analysis was performed offline by the customised software for Vivid (2D-strain EchoPac PC v.7.0.1, GE Healthcare, Horten, Norway). Basal and apical parasternal short axis views were recorded for each patient. The basal plane was defined as that allowing visualization of the mitral valve with the cross-section as circular as possible. The apical plane was acquired distally to the papillary muscles [15]. LV twist was calculated as the net difference in peak systolic rotational strain between the six basal and six apical segments.

While acquiring two-dimensional images we kept the focus position at intermediate depth and adjusted the sector depth and width to include little but the region of interest. Furthermore, the sampling region of interest was adjusted to ensure that most of the wall thickness was incorporated in the analysis avoiding the pericardium. Frame rate was between 60 frames/s and 80 frames/s.

Arterial stiffness parameters
On the same day, around 10 min after performing the echocardiogram, blood pressure was measured with the subjects in supine position. Pressure waveforms were recorded on the radial, carotid and femoral arteries using applanation tonometry [16]. Carotid-femoral aPWV was calculated using a commercially available device (SphygmoCor, Pulse Wave Analysis System, AtCor Medical), with a high-fidelity Millar strain-gauge transducer (Millar Instruments, Houston, TX) as described previously [6]. Two separate operators conducted the measurements with coefficient of variation of <10 %.

Previous studies have demonstrated that a aPWV cut off of 10 m/s has been shown to provide risk stratification and prognostic value in CKD patients [17]. Therefore, in our study we defined increased aPWV as ≥10 m/s.

Reproducibility
In order to test inter and intra-observer variability for both LV Twist and aPWV indices, we reassessed the measurements on a sub-group of 20 randomly selected patients. Shortly after the first assessment a second operator, who was blinded to the results, analysed aPWV and LV twist. Subsequently the first operator re-measured the same indices.
**Statistical analysis**

Statistical analysis was performed using SPSS software, version 22 (IBM, Armonk, NY). Variables were tested for normality by the Kolmogorov-Smirnov test. Firstly, analysis was performed by dividing the patients into 2 groups; one with aPWV < 10 m/s and the other with PWV ≥ 10 m/s. Differences between the 2 groups were analyzed using chi-square test for categorical data, t-test for continuous normally distributed data and Wilcoxon rank sum test for continuous non-normally distributed data. Correlations were assessed for normal and non-normal variables using Pearson’s and Spearman’s coefficients respectively. Univariate and multivariate analyses were used to evaluate the relationship between, arterial stiffness and a range of variables including general demographics, cardiovascular risk factors, conventional echocardiographic and speckle tracking parameters including LV Twist. Intraclass correlation coefficients (ICC) and Bland-Altman plots were determined to assess the inter-operator and intra-operator variability of speckle tracking and arterial stiffness measurements. The criterion for statistical significance used was a P-value of ≤0.05 to a 95 % confidence interval.

**Results**

Inter- and intra-operator variability of speckle tracking and arterial stiffness parameters

Inter-operator variability (n = 20): the ICC for LV twist 0.80, p < 0.001.

Intra-operator variability (n = 20): the ICC for LV twist 0.89, p < 0.001.

The strength of agreement for intra-observer and inter-observer measurements of aPWV is shown in Fig. 1.

Figure 2 is a Bland-Altman plot showing inter-observer variability of aPWV and LV Twist.

Feasibility of obtaining 2D speckle tracking deformation indexes

Deformation parameters could not be quantified in 15 patients due to sub-optimal echodiagnostics windows (n = 9).

**Clinical and echocardiographic characteristics**

95 CKD patients (89.6 %) underwent renal biopsy to determine the cause of their CKD. The most common CKD aetiology was diabetes (N = 30), followed by vasculitis (N = 18), post-renal causes (N = 10), IgA nephropathy (N = 7), focal glomerulosclerosis (N = 6), membranous glomerulonephritis (N = 5), hypertension (N = 4), adult polycystic kidney disease (N = 3), renovascular disease (N = 3), and minimal change disease (N = 3). In six patients, aetiology was unknown.

Patients were stratified in two different groups according to aPWV: normal aPWV <10 m/s, increased aPWV ≥ 10 m/s. Table 1 shows patients clinical characteristics. Participants with increased aPWV were more likely to have diabetes (p < 0.001) and hypertension (p < 0.001) and lower eGFR (p < 0.001). Table 2 displays echocardiographic parameters across the two groups. Patients with increased aPWV had lower TDI S′ (p = 0.03), global longitudinal strain (GLS) (p = 0.002), higher LVMI (p = 0.01), E/e′ (p = 0.01), LV Twist (p < 0.001) - Fig. 4 but similar LVEF (p = 0.482). Table 3 shows the variation in LV Twist and in aPWV as we move from early to late CKD stages.

Univariate association of aPWV with demographics, risk factors and echocardiographic parameters

Table 4 displays univariate correlations of aPWV with clinical and echocardiographic parameters. Aortic PWV correlated crudely with age (p < 0.001), the presence of diabetes (p < 0.001), hyperlipidemia (p = 0.013), peripheral SBP (p < 0.001), hypertension (p < 0.001), eGFR (p < 0.001), LVMI (p < 0.001), E/e′ (p < 0.001), TDI S′ (p = 0.03), GLS (p = 0.01) and LV twist (p = 0.003). Figure 5 is a scatter plot demonstrating the correlation between aPWV and LV Twist.
Multivariable analysis
In the linear regression model, aPWV was independently associated with age ($\beta = 0.467$, $p < 0.001$), diabetes ($\beta = 0.532$, $p < 0.001$), hypertension ($\beta = 0.158$, $p = 0.05$), eGFR ($\beta = -0.234$, $p = 0.008$), LMVI ($\beta = 0.143$, $p < 0.042$) and LV twist ($\beta = 0.163$, $p = 0.025$) Table 4.

Discussion
To our knowledge this is the first study to associate aPWV, a marker of aortic stiffness, with LV twist, a myocardial deformation index. The independent association between LV twist and aPWV in asymptomatic CKD patients, suggests an interplay between arterial and ventricular mechanics early on in the cardiovascular disease continuum.

Arterial remodeling has been described in early stage CKD [18]. Compared with normotensive and hypertensive controls, patients with CKD stages 2–5 had significantly larger internal carotid artery diameters but comparable intima-media thickness, resulting in significantly increased circumferential wall stress [18]. Furthermore the recent Nephrotest study [19] identified aPWV velocity as an independent predictor of all cause mortality and fatal or non-fatal cardiovascular events in 439 patients with CKD.
stages 3–5. The same study demonstrated that the addition of PWV to traditional risk factors significantly improved the risk stratification for all-cause mortality. Arterial stiffness in early CKD patients has been associated with the presence of diastolic dysfunction [20] and increased LV mass [21]. However, its relationship with systolic function remains poorly investigated and largely unknown. Evaluation of systolic function in CKD patients has traditionally been limited to volume-based assessment of LVEF and assessment of regional wall motion or visual estimation of regional thickening. Although LVEF is one of the most powerful echocardiographic predictors of death or cardiovascular morbidity, it is not a sensitive marker of global LV systolic function in the presence of LV hypertrophy (commonly present in CKD patients) [22]. Additionally, LVEF may be insufficiently sensitive to identify mild degrees of systolic dysfunction as proven by its inability to identify a gradation of risk in patients with EF >45% [23]. This suggests that asymptomatic CKD patients can have myocardial dysfunction with preserved LVEF. Deformation imaging using STE may overcome this limitation. Speckle tracking echocardiography

| Table 1 Clinical characteristics according to aPWV groups |
|----------------------------------------------------------|
|                                                         |
| Normal PWV <10 m/s | Increased PWV ≥ 10 m/s | p-value |
|---------------------|-------------------------|---------|
| Clinical demographics |                         |         |
| Age 51.2 ± 14       | 63 ± 12                 | <0.001* |
| Male gender (%)     | 45.4                    | 41.2    | 0.455   |
| BSA (g/m2) 1.88 ± 0.21 | 1.87 ± 0.22           | 0.906   |
| Cardiovascular risk factors |               |         |
| BMI (g/m2) 26.9 ± 5 | 27.8 ± 5.1              | 0.367   |
| eGFR (mL/min/1.73 m²) 48.95 ± 20.1 | 30.5 ± 15.4           | <0.001* |
| Systolic BP (mmHg) 127.2 ± 20.4 | 140.5 ± 18.5          | 0.01*   |
| Diastolic BP (mmHg) 77.9 ± 10.6 | 79.5 ± 10.5           | 0.451   |
| Diabetes (%) 20.3 | 71                      | <0.001* |
| Hypertension (%) 62.5 | 82.8                  | <0.001* |
| Family history of IHD (%) 29.7 | 26.8               | 0.755   |
| Smoking status (%) Current |               |         |
| Current 6.3         | 9.8                     | 0.295   |
| Ex 9.4              | 9.8                     |         |
| Never 45.3          | 34.1                    |         |
| Medication |                         |         |
| Aspirin (%) 28       | 37                      | 0.367   |
| Clopidogrel (%) 2     | 7                       | 0.135   |
| ACE-I (%) 34         | 69                      | <0.001* |
| ARBs (%) 53          | 51                      | 0.858   |
| Beta-blockers (%) 16 | 22                      | 0.416   |
| CCB dihydropyridine (%) 25 | 38               | 0.151   |
| Loop diuretic (%) 22 | 34                      | 0.112   |
| Thiazide diuretic (%) 2 | 10                     | 0.06    |
| Any antihypertensive (%) 40.1 | 87.2           |         |
| Statins (%) 61       | 80                      | 0.110   |
| Prednisolone (%) 22  | 10                      | 0.125   |
| Metformin (%) 9      | 18                      | 0.081   |
| Gliclazide (%) 9     | 12                      | 0.649   |
| Insulin (%) 8        | 41                      | <0.001* |

BSA body surface area; BMI body mass index; GFR glomerular filtration rate; CKD chronic kidney disease; BP blood pressure; ARB angiotensin II receptor blocker; CCB calcium channel blocker; IHD ischemic heart disease; ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin II receptor blocker

*Statistically significant difference between the two groups
follows the motion of myocardial tissue throughout the cardiac cycle by tracking acoustic reflections, known as speckles, in previously obtained echocardiographic images. Recently two studies explored the relationship of GLS, a marker of subclinical systolic dysfunction and arterial stiff-
ness. Krishnasamy et al. demonstrated an independent association between GLS, assessed by STE, and aPWV in patients with CKD stages 3–5 [24]. Kim and colleagues also found an independent association between brachialankle PWV and GLS [25]. Concurring to our findings the authors identified a close interaction between arterial stiffness and LV function. However the aforementioned studies are limited by the fact that novel elements of deformation such as LV twist were not investigated.

Alterations in LV twist have been linked with subclinical myocardial dysfunction in a variety of clinical settings [26–28], nonetheless its association with arterial stiffness has never been studied. To our knowledge the current study is the first to find an independent association between LV twist and aPWV. With increased aPWV, the reflected waves return earlier, impacting on the central arteries during systole rather than diastole thus amplifying aortic and ventricular systolic pressures. As a consequence myocardial pressure load and oxygen consumption

| Table 2 Echocardiographic characteristics according to aPWV groups | Normal PWV <10 m/s | Increased PWV ≥ 10 m/s | p-value |
|---------------------------------------------------------------|---------------------|------------------------|--------|
|                                                             | n = 64              | n = 42                 |        |
| Conventional echocardiography                                 |                     |                        |        |
| Simpsons biplane EF (%)                                       | 62.9 ± 5            | 61.3 ± 4.7             | 0.48   |
| TDI S’ – septal (cm/s)                                        | 10.6 ± 2.4          | 8.6 ± 1.9              | 0.03*  |
| LVMi (g/m²)                                                   | 63.7 ± 19           | 78.4 ± 22              | 0.01*  |
| RWT                                                          | 0.44 ± 0.09         | 0.51 ± 0.12            | 0.001* |
| E/e’ (average)                                                | 8.9 ± 3.7           | 10.8 ± 4.2             | 0.01*  |
| LA (cm)                                                      | 3.68 ± 0.58         | 3.9 ± 0.63             | 0.001* |
| Diastolic dysfunction (%)                                     |                     |                        |        |
| Not present                                                   | 40.6                | 22.5                   | 0.001* |
| Type 1                                                       | 50                  | 40                     |        |
| Type 2                                                       | 9.4                 | 34.9                   |        |
| LV Twist (°)                                                  | 19.8 ± 5.4          | 23.5 ± 5.7             | <0.001*|
| GLS(%)                                                       | −19.6 ± 3.3         | −17.1 ± 2.9            | 0.002* |
| GCS(%)                                                       | −23.3 ± 4.3         | −22.8 ± 4.9            | 0.159  |

LVMI left ventricular mass index; RWT regional wall thickness; EF ejection fraction; LV left ventricle, GLS Global longitudinal strain; GCS Global circumferential strain

*Statistically significant difference between groups

![Patient with normal PWV LV Twist 17.6°](image1)

![Patient with increased PWV LV Twist 21.3°](image2)

**Fig. 4** LV twist in a patient with normal and increased PWV
increase, leading to subendocardial injury [2, 3]. Myocardial fiber orientation changes continuously from a right-handed helix in the subendocardium to a left-handed helix in the subepicardial region [9]. Subepicardial layers dominate the overall rotation/twist during ejection and remain preserved in early myocardial disease [9]. Subendocardial fibres counteract subepicardial dominance and are the most vulnerable and sensitive to the presence of early myocardial disease. Subendocardial injury would therefore exaggerate overall LV twist as the subepicardial fibres would function in the absence of the counteracting subendocardial ones. A similar mechanism has been identified in patients with diastolic heart failure [29]. The current findings highlight that the cardiovascular system should always be viewed as an entity. When subclinical abnormalities are detected in the heart one

Table 3 Echocardiographic and arterial stiffness parameters across CKD stages

|                      | CKD stage 1/2 | CKD stage 3 | CKD stage 4/5 | p value\(^a\) | Adjusted p value\(^b\) |
|----------------------|---------------|-------------|---------------|---------------|------------------------|
| Simpsons biplane EF (%) | 63.7 ± 5.5    | 62.3 ± 4.9  | 62.5 ± 4.9    | 0.617         | 0.838                  |
| LVMI (g/m\(^2\))     | 60.5 ± 20     | 70 ± 19.8   | 75.6 ± 24.1   | 0.003\(^*\)   | 0.085\(^*\)            |
| Concentric remodelling (%RWT > 0.42) | 31            | 52.6        | 72.3          | <0.001\(^*\)  | <0.001\(^*\)           |
| E/e' (average)       | 6.96 ± 2.25   | 9.41 ± 3.87 | 9.92 ± 3.96   | <0.001\(^*\)  | 0.013\(^*\)            |
| TDI S' - septal (cm/s)| 11 ± 2.7      | 10.6 ± 3.7  | 9.1 ± 2.3     | 0.02\(^*\)    | 0.03\(^*\)             |
| LV Twist (°)         | 18.5 ± 4.4    | 19.9 ± 5.4  | 24.6 ± 5.4    | <0.001\(^*\)  | <0.001\(^*\)           |
| PWV(m/s)             | 7.7 ± 2       | 10.3 ± 3.3  | 12.5 ± 4.2    | <0.001\(^*\)  | 0.001\(^*\)            |

LVEF left ventricular ejection fraction; LVMI left ventricular mass index; RWT regional wall thickness; LV left ventricular; PWV pulse wave velocity

\(^a\)Statistically significant difference between: \(^\text{CKD stage 1/2 and CKD stage 3, CKD stage 1/2 and CKD stage 4/5, CKD stage 3 and CKD stage 4/5}\)

\(^b\)Adjusted for age, gender, diabetes, SBP, BMI, treated hyperlipidaemia, eGFR and family history of ischaemic heart disease

Table 4 Univariate and multivariate analysis of aPWV

|                       | Crude Standardized β | P-value | Adjusted\(^a\) Standardized β | p-value | Adjusted\(^b\) Standardized β | p-value |
|-----------------------|----------------------|---------|-------------------------------|---------|-------------------------------|---------|
| Age                   | 0.635                | <0.001* | 0.492                         | 0.001*  | 0.467                         | 0.001*  |
| Gender                | −0.172               | 0.079   | −0.019                        | 0.654   | −0.013                        | 0.691   |
| BSA (g/m2)            | 0.27                 | 0.187   | 0.031                         | 0.238   | 0.345                         | 0.459   |
| Hemoglobin (g/L)      | −0.150               | 0.131   | −0.059                        | 0.481   | −0.098                        | 0.221   |
| Hyperlipidemia        | 0.242                | 0.013*  | 0.118                         | 0.144   | 0.065                         | 0.433   |
| Peripheral systolic BP (mmHg) | 0.397             | <0.001* | 0.185                         | 0.024*  | 0.169                         | 0.059   |
| Diabetes (%)          | 0.589                | <0.001* | 0.555                         | <0.001* | 0.532                         | <0.001* |
| Hypertension (%)      | 0.308                | <0.001* | 0.294                         | 0.013*  | 0.158                         | 0.050*  |
| BMI (g/m2)            | 0.055                | 0.579   | −0.156                        | 0.063   | −0.133                        | 0.118   |
| eGFR (ml/min/1.73 m\(^2\)) | −0.410             | <0.001* | −0.259                        | 0.003*  | −0.234                        | 0.008*  |

Echocardiographic parameters

|                       | Crude Standardized β | P-value | Adjusted\(^a\) Standardized β | p-value | Adjusted\(^b\) Standardized β | p-value |
|-----------------------|----------------------|---------|-------------------------------|---------|-------------------------------|---------|
| Simpsons biplane EF(%)| −0.117               | 0.237   | −0.036                        | 0.646   | −0.094                        | 0.634   |
| TDI S’ - septal (cm/s)| 0.186                | 0.03*   | 0.120                         | 0.058   | 0.101                         | 0.093   |
| E/e’(average)         | 0.387                | <0.001* | 0.192                         | 0.022*  | 0.113                         | 0.089   |
| LVMI (g/m\(^2\))     | 0.379                | <0.001* | 0.165                         | 0.03*   | 0.143                         | 0.042*  |
| LV Twist(°)           | 0.388                | 0.003*  | 0.181                         | 0.019*  | 0.163                         | 0.025*  |
| GLS(%)                | 0.300                | 0.01*   | 0.186                         | 0.09    | 0.060                         | 0.130   |
| GCS(%)                | 0.046                | 0.197   | 0.018                         | 0.458   | 0.010                         | 0.634   |

Standardized coefficients (β) refer to how many SDs a dependent variable (aPWV) will change, per standard deviation increase in the predictor variable. \(n = 106\)

\(^*\)statistically significant

CKD chronic kidney disease; BSA body surface area; BP blood pressure; LVMI left ventricular mass index; eGFR estimated glomerular filtration rate; EF ejection fraction; LV left ventricular

\(^a\)Adjusted for age, gender, diabetes, SBP, BMI, treated hyperlipidaemia, eGFR and family history of ischaemic heart disease

\(^b\)Adjusted for factors in Model 2 plus antihypertensive medication (b-blockers, dihydropyridine calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers) and prednisolone
should also consider exploring the presence of early disease in the peripheral arterial system and vice versa. Patients with isolated hypertension [30], heart failure with normal LVEF [31], diabetes mellitus [32] or CKD [2] could potentially benefit of STE or aPWV for early identification of CVD. However, it should be noted that although STE has been validated against sonomicrometry and CMR, vendor reproducibility [33], the need for optimal image quality and time constraint are limiting STE use in routine clinical practice. However, strain imaging using STE could be used as a supplementary diagnostic method in several conditions [34]; (i) to identify early systolic dysfunction in patients with normal or preserved LVEF [8, 35], (ii) to identify subclinical LV dysfunction in individuals who are evaluated for cardiomyopathy [36], (iii) in addition to LVEF in patients undergoing chemotherapy to identify sub-clinical LV dysfunction [37].

Future randomized control studies are required to assess the potential benefit of early, aggressive risk factor management in asymptomatic CKD patients with abnormal LV twist/aPWV indices. For the time being, physicians should consider initiation of risk factor modification therapies in CKD patients with abnormal LV twist or PWV parameters, even in the absence of high CVD risk using established calculators (Q-risk, Framingham, etc).

Limitations
Firstly due to the observational design of the study we cannot determine causality between subclinical 2DSTE abnormalities and aPWV and our results should be viewed as hypothesis generating. Secondly, even though patients recruited in the current study were asymptomatic from the cardiovascular point of view, with no previous history of ischaemic heart disease and a structurally normal heart on transthoracic echocardiogram, the presence of significant coronary artery disease was not ruled out with a functional or invasive test. However, in a subset of 20 pre-dialysis patients who subsequently underwent elective invasive angiography as part of their pre-transplant assessment, the vast majority 19 (95 %), had no significant disease in their epicardial arteries. This fact supports the hypothesis that microvascular ischaemia may be accountable for the LV twist patterns observed in our CKD population.

Conclusions
In summary the current study provides for the first time a link between LV twist assessed by STE and early peripheral arterial disease, in asymptomatic CKD patients with preserved LVEF. Future studies of patients with these early subclinical markers of CVD should be undertaken, randomizing their participants to aggressive risk factor management versus watchful waiting. If early risk factor modification in patients with abnormal LV twist and PWV values improves outcomes, these markers could be used for risk stratification purposes in this population.

Abbreviations
aPWV: Aortic pulse wave velocity; CKD: Chronic kidney disease; CVD: Cardiovascular disease; GLS: Global longitudinal strain; ICC: Intraclass correlation coefficients; LV: Left ventricle; LVEF: Left ventricular ejection fraction; LVMI: LV mass index; STE: Speckle-tracking echocardiography.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors made significant contributions and participated sufficiently in the present manuscript. SS, VP, AT and PN conceived the study. SS, VP, KC and AT were involved in recruitment, data collection, data (statistical) analysis and were also involved in the writing process and critical analyses. FT and EB were involved in the recruitment process and manuscript review. PN was involved in all aspects of this manuscript. All authors read and approved the final manuscript.
Acknowledgements
Samir Sulemane received a doctoral research grant from Fundação para a Ciência e Tecnologia (FCT) under the grant number SFRH/BD/73646. The authors would like to thank Dr. Julia Grapsa for her contribution in the conception of the manuscript.

Author details
1 Imperial College London, National Heart and Lung Institute, Sydney Street, SW6 3NP London, UK. 2 Imperial College Healthcare NHS, Hammarsmith Hospital, Ducane road, W12 0HP London, UK. 3 Imperial College Renal and Transplant Centre, Hammersmith Hospital, Ducane road, W12 OHP London, UK.

Received: 17 December 2015 Accepted: 2 March 2016
Published online: 09 March 2016

References
1. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45(3):494–501.
2. Chue CD, Townsend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart. 2010;96(11):817–23.
3. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50(2):600–8.
4. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(12):2588–605.
5. O’Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness: definitions and reference values. Am J Hypertens. 2002;15(5):426–44.
6. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–8.
7. Frimodt-Moller M, Nielsen AH, Kamper AL, Strandgaard S. Reproducibility of pulse-wave analysis and pulse wave velocity determination in chronic kidney disease. Nephrol Dial Transplant. 2008;23(2):594–600.
8. Panoulas VF, Sulemane S, Konstantinou K, Bratsas A, Elliott SJ, Dawson D, et al. Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease. Eur J Cardiovasc Imaging. 2015;16(5):539–48.
9. Sengupta PP, Tajik AJ, Chandrasekaran K, Bratsas A, Elliott SJ, Dawson D, et al. Left ventricular torsion: an expanding role in the analysis of myocardial function. JACC Cardiovasc Imaging. 2008;1(3):366–76.
10. Reznik IK, Gomts MI, Bronzwaer JG, Knaepen P, Paulus WJ, van Rossum AC. Left ventricular torsion: an expanding role in the analysis of myocardial dysfunction. JACC Cardiovasc Imaging. 2009;2(5):648–55.
11. Zhang HJ, Wang H, Sun T, Lu MJ, Xu N, Wu WC, et al. Assessment of left ventricular twist mechanics by speckle tracking echocardiography reveals association between LV twist and myocardial fibrosis in patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2014;30(8):1539–48.
12. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol. 2006;47(4):789–93.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.
14. Lang RM, Badano LP, Mor-Avi V, Agler MD, Armstrong A, Bierig M, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–70.
15. van Dalen BM, Vletter WB, Solliman OI, ten Cate FJ, Geleijnse ML. Importance of transducer position in the assessment of apical rotation by speckle tracking echocardiography. J Am Soc Echocardiogr. 2008;21(8):895–8.
16. Ring M, Eriksson MJ, Zierath JR, Caidahl K. Arterial stiffness estimation in healthy subjects: a validation of oscillographic (Arteriograph) and tonometric (SpymgoCor) techniques. Hypertens Res. 2014;37(11):999–1007.
17. Baumann M, Wasserteuner S, Suttmann Y, Burkhardt K, Heemann U. Aortic pulse wave velocity predicts mortality in chronic kidney disease stages 2–4. J Hypertens. 2013;32(4):899–903.
18. Brier M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 2006;69(2):350–7.
19. Karras A, Haymann JP, Bozec E, Metzger M, Jacquot C, Marana I, et al. Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease. Hypertension. 2012;60(6):1451–7.
20. Edwards NC, Ferro CJ, Townsend JN, Steeds RP. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart. 2009;94(8):1038–43.
21. Henry RM, Kamp O, Kostense PJ, Spiekerman AM, Dekker JM, Nijpels G, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: an arterial stiffness-related phenomenon—the Hoorn Study. Kidney Int. 2005;68(2):673–9.
22. Chiu DY, Green D, Abdin N, Sinha S, Kall PA. Cardiac imaging in patients with chronic kidney disease. Nat Rev Nephrol. 2015;11(4):207–20.
23. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadwaee F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42(4):736–42.
24. Kristinssamy R, Hawley CM, Stanton T, Pascoe EM, Campbell KL, Rossi M, et al. Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. BMC Nephrol. 2015;16:106.
25. Kim HL, Seo JB, Chung WY, Kim SH, Kim MA, Zo JH. Independent association between brachial-ankle pulse wave velocity and global longitudinal strain of left ventricle. Int J Cardiovasc Imaging. 2015;31(18):1563–70.
26. Pacileo G, Baldini L, Limongelli G, Di Salvo G, Iacomino M, Capogrosso C, et al. Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr. 2011;12(11):841–9.
27. Santoro A, Alvino F, Antonelli G, Zaca V, Benincasa S, Lunghetti S and Mondillo S. Left Ventricular Twisting Modifications in Patients with Left Ventricular Concentric Hypertrophy at Increasing After-Load Conditions. Echocardiography. 2014. doi:10.1111/echo.12555.
28. Takeuchi M, Nishikage T, Nakai H, Kokumai M, Otani S, Lang RM. The assessment of left ventricular twist in anterior wall myocardial infarction using two-dimensional speckle tracking imaging. J Am Soc Echocardiogr. 2007;20(1):36–44.
29. Wang J, Khoury DS, Yue Y, Torre-Amione G, Naguef SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J. 2008;29(10):1283–9.
30. Zheng M, Huo Y, Wang X, Xu X, Qin X, Tang G, et al. A prospective study on pulse wave velocity (PWV) and response to anti-hypertensive treatments: PWV determines BP control. Int J Cardiol. 2015;178:226–31.
31. Kovacs A, Papp Z, Nagy L. Causes and pathophysiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):389–98.
32. Huang L, Yang L, Zhang S, Liu D, Yan X, Yan S. Low-grade albuminuria associated with brachial-ankle pulse wave velocity in young adults with type 2 diabetes mellitus in China. Diabetes Metab Res Rev. 2014. doi:10.1002/dmr.2598.
33. Manovell A, Dawson D, Smith B, Nihoyannopoulos P. Assessment of left ventricular function by different speckle-tracking software. Eur J Echocardiogr. 2010;11(5):417–21.
34. Smiseth OA, Torp H, Opdal A, Haugaa KH, Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. 2015. doi:10.1093/eurheartj/het529.
35. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Shanks M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104(10):1398–401.
36. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.
37. Stoodley PW, Richards DA, Boyd A, Hui R, Hamnett PR, Meikle SR, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J. Cardiovasc Imaging. 2013;14(3):228–34.